DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate, as a potent EGFR inhibitor and it overcomes resistant to EGFR.
Structure of 1228105-51-8
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
10 mg | $298 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
DM1-SMCC, a potent cytotoxic agent, plays a vital role in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. Here are four key applications of DM1-SMCC:
Cancer Treatment: At the forefront of targeted cancer therapy, DM1-SMCC is a cornerstone in ADCs engineered to specifically seek out cancer cells. By binding to antibodies that recognize tumor-associated antigens, this cytotoxic agent is delivered directly to malignant cells, minimizing harm to healthy tissues. This precision targeting not only enhances treatment effectiveness but also reduces systemic side effects, heralding a paradigm shift in cancer care.
Pharmacokinetics Studies: In the realm of pharmacokinetics research, DM1-SMCC is a crucial tool for unraveling the behavior and distribution of ADCs in both preclinical and clinical settings. Understanding the journey of these conjugates in the body—from absorption to elimination—is paramount for optimizing dosing strategies and improving therapeutic results. These studies are instrumental in predicting clinical responses and potential adverse reactions.
Drug Development: Serving as a prototypical payload, DM1-SMCC plays a pivotal role in designing the next generation of ADCs. By manipulating linker chemistry or pairing with diverse monoclonal antibodies, scientists can craft innovative ADCs with enhanced stability, potency, and selectivity. This adaptability is key to tailoring treatments for a spectrum of cancer types.
Mechanism of Action Studies: Delving into the intricate mechanisms of ADCs’ cytotoxic effects on cancer cells, DM1-SMCC empowers researchers to explore cellular uptake, intracellular trafficking, and release within targeted cells. These investigations offer profound insights into how ADCs induce cell death, shedding light on resistance mechanisms and optimizing therapeutic approaches. This deep understanding is pivotal for refining cancer treatment strategies and overcoming therapeutic challenges.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01450 | MCC-DM1 | 1100692-14-5 | |
BADC-00574 | Lys-SMCC-DM1 | 1281816-04-3 | |
BADC-00848 | MC-DM1 | 1375089-56-7 | |
BADC-00020 | DM1-SMe | 138148-68-2 | |
BADC-00601 | Mal-VC-PAB-DM1 | 1464051-44-2 | |
BADC-00668 | SC-VC-PAB-DM1 | 2259318-47-1 | |
BADC-00010 | DM1-SPP | 452072-20-7 | |
BADC-01378 | S-methyl DM1 | 912569-84-7 | |
BADC-01407 | SPDB-DM1 | ||
BADC-01411 | MPB-VC-PAB-DM1 |
What is DM1-SMCC?
DM1-SMCC is an ADC linker-payload that combines the payload DM1 with the linker SMCC. DM1 is a maytansinoid, a potent cytotoxic agent, and SMCC (Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) is a non-cleavable maleimide-based linker. This construct is used to create stable ADCs for targeted drug delivery.
17/2/2018
Dear team, how does the SMCC linker function in ADCs?
The SMCC linker provides a stable covalent connection between the DM1 payload and the antibody. It contains a maleimide group that reacts with the sulfhydryl groups of reduced cysteine residues on the antibody, and an N-hydroxysuccinimide (NHS) ester that forms an amide bond with the DM1 payload. This non-cleavable linker is designed to ensure the ADC remains intact in circulation.
10/11/2022
We are interested in understanding the mechanism of action of the DM1 payload.
The DM1 payload is a derivative of maytansine. It is a tubulin inhibitor that disrupts microtubule dynamics within cancer cells, leading to mitotic arrest and subsequent apoptosis. Its mechanism of action is crucial for its potent antimitotic activity, making it an effective payload for targeted cancer therapy.
3/3/2021
Could you kindly explain why the non-cleavable SMCC linker is important?
The non-cleavable nature of the SMCC linker is a key feature. By forming a highly stable thioether bond with the antibody, it prevents the premature release of the cytotoxic DM1 payload in the bloodstream. This characteristic minimizes off-target toxicity and ensures the payload is delivered specifically to the tumor cells, where it can be released and exert its effect.
24/9/2022
Good morning! What is the difference between DM1 and other maytansinoids?
DM1 is a derivative of maytansine. It has been modified to include a disulfide bond that allows for its conjugation to antibodies. Unlike some other maytansinoids, DM1 is designed for use with specific linkers like SMCC, making it a stable and effective component in ADCs with a proven track record.
16/11/2016
— Dr. Richard Evans, Senior Scientist (USA)
DM1-SMCC purity exceeded our expectations, which is critical for reliable ADC conjugation.
3/3/2021
— Dr. Victoria Brown, ADC Chemist (UK)
We found the delivery speed of DM1-SMCC particularly helpful for urgent preclinical studies.
16/11/2016
— Dr. Stefan Weber, Medicinal Chemist (Germany)
Detailed technical notes on DM1-SMCC allowed our team to optimize linker-toxin ratios efficiently.
24/9/2022
— Dr. Emily Grant, Biochemist (Canada)
Consistent batch performance of DM1-SMCC reduced experimental variability across replicates.
17/2/2018
— Dr. Thomas Wright, Lead Scientist (USA)
High-purity DM1-SMCC with regulatory documentation simplified our internal validation procedures.
— Dr. Isabelle Moreau, Research Scientist (France)
The combination of DM1-SMCC quality and BOC Sciences’ expert support accelerated project milestones.
10/11/2022
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.